Nxera Pharma signs exclusive supply and distribution deal with Handok for PIVLAZ™ in South Korea.

Nxera Pharma, a tech-driven biopharma company, has entered an exclusive supply and distribution agreement with South Korean pharmaceutical leader Handok. Nxera will provide PIVLAZ™, the first drug approved in South Korea for preventing cerebral vasospasm in aneurysmal subarachnoid hemorrhage patients, to Handok for marketing, sales, and distribution. The partnership aims for PIVLAZ™'s commercial availability in South Korea in early 2025, with Nxera receiving upfront payment, milestone payments, and sales proceeds from product supply.